MDXG Relative Valuation
MDXG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MDXG is overvalued; if below, it's undervalued.
Historical Valuation
MiMedx Group Inc (MDXG) is now in the Fair zone, suggesting that its current forward PS ratio of 2.58 is considered Fairly compared with the five-year average of 3.82. The fair price of MiMedx Group Inc (MDXG) is between 4.92 to 9.17 according to relative valuation methord.
Relative Value
Fair Zone
4.92-9.17
Current Price：6.42
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
4.89
P/B
Median3y
43.66
Median5y
-7.73
6.52
FCF Yield
Median3y
1.15
Median5y
-0.58
Competitors Valuation Multiple
The average P/S ratio for MDXG's competitors is 2.79, providing a benchmark for relative valuation. MiMedx Group Inc Corp (MDXG) exhibits a P/S ratio of 2.58, which is -7.44% above the industry average. Given its robust revenue growth of 4.13%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is MiMedx Group Inc (MDXG) currently overvalued or undervalued?
What is MiMedx Group Inc (MDXG) fair value?
How does MDXG's valuation metrics compare to the industry average?
What is the current P/B ratio for MiMedx Group Inc (MDXG) as of Jul 19 2025?
What is the current FCF Yield for MiMedx Group Inc (MDXG) as of Jul 19 2025?
What is the current Forward P/E ratio for MiMedx Group Inc (MDXG) as of Jul 19 2025?